Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) EPS (Basic) (2022 - 2025)

Historic EPS (Basic) for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to -$0.52.

  • ARS Pharmaceuticals' EPS (Basic) fell 16000.0% to -$0.52 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.82, marking a year-over-year decrease of 6078.43%. This contributed to the annual value of $0.08 for FY2024, which is 11447.5% up from last year.
  • Per ARS Pharmaceuticals' latest filing, its EPS (Basic) stood at -$0.52 for Q3 2025, which was down 16000.0% from -$0.46 recorded in Q2 2025.
  • ARS Pharmaceuticals' 5-year EPS (Basic) high stood at $0.49 for Q4 2024, and its period low was -$0.52 during Q3 2025.
  • For the 4-year period, ARS Pharmaceuticals' EPS (Basic) averaged around -$0.2, with its median value being -$0.2 (2024).
  • Its EPS (Basic) has fluctuated over the past 5 years, first skyrocketed by 79554.99% in 2024, then plummeted by 25384.62% in 2025.
  • Quarter analysis of 4 years shows ARS Pharmaceuticals' EPS (Basic) stood at -$0.39 in 2022, then skyrocketed by 81.89% to -$0.07 in 2023, then skyrocketed by 795.55% to $0.49 in 2024, then tumbled by 206.8% to -$0.52 in 2025.
  • Its EPS (Basic) was -$0.52 in Q3 2025, compared to -$0.46 in Q2 2025 and -$0.35 in Q1 2025.